A widely prescribed steroid is designed to act mainly where it is applied

A widely prescribed steroid is designed to act mainly where it is applied
Image: Intellect (generated)

In short: Fluticasone propionate is a steroid used to manage asthma, COPD, hay fever and nasal polyps. Inhaled or sprayed into the nose, it is meant to work locally, with only limited amounts reaching the bloodstream. Its story shows why dosing and drug interactions still matter, even for a medicine prescribed millions of times a year.

Fluticasone propionate is a glucocorticoid steroid. When inhaled, it is used for the long-term control of asthma and chronic obstructive pulmonary disease. In the nose, it treats hay fever and nasal polyps, and a nasal spray form can also be used for mouth ulcers. As a topical preparation, it is applied to skin conditions such as eczema, psoriasis and rashes. The compound was patented in 1980, received approval for medical use in 1990, and is now sold as a generic.

The drug acts by binding tightly to the glucocorticoid receptor, while showing very little activity at the receptors for androgens, estrogens or mineralocorticoids. It dampens inflammation by inhibiting many cell types and chemical messengers involved in the immune response, including histamine, leukotrienes and cytokines. Because little of it enters the circulation at usual doses, its main effect is described as local, particularly in the lungs.

Low absorption is not the same as no absorption. The nasal and inhaled forms produce fewer corticosteroid side effects than the tablet form, yet some of the drug still reaches the blood. Taking more than the recommended amount, or combining it with other corticosteroids, raises the risk of serious whole-body effects, including a weakened immune system, infections, bone thinning and raised pressure inside the eye. The liver enzyme CYP3A4 breaks the drug down, so strong inhibitors such as ritonavir and ketoconazole can increase its levels, which may in turn bring on Cushing's syndrome and adrenal insufficiency.

Its prescribing footprint is large. In 2023 it ranked 26th among medicines prescribed in the United States, with over 21 million prescriptions. Rules also differ between products: the nasal form is approved for children aged four and older, whereas a related compound, fluticasone furoate, is approved for allergies from age two. In 2024, GSK withdrew the Flovent brand and substituted an authorised generic version.

theme mood

difficulty topics

claims canvas home

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-fluticasone-propionate.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…